The Neurology Minute® podcast delivers a brief daily summary of what you need to know in the field of neurology, the latest science focused on the brain, and timely topics explored by leading neurologists and neuroscientists. From the American Academy of Neurology and hosted by Stacey Clardy, MD, PhD, FAAN, with contributions by experts from the Neurology® journals, Neurology Today®, Continuum®, and more.
Emerging migraine therapy is moving beyond CGRP, but trial signals still need disciplined interpretation. A useful bedside lesson is to document cranial autonomic symptoms and prior CGRP response carefully, because new peptide targets may help selected patients without yet replacing established treatments.
Refractory migraine is not simply frequent headache. Confirm migraine rather than another diagnosis, document burden and monthly migraine days, and remember treatment only counts as failed if benefit stays below 50%, adverse effects are intolerable, or the drug is contraindicated.
Temporary telehealth extensions are not a safe continuity plan. In neurology, delayed follow-up and prior-authorisation barriers should be treated as patient safety problems, so clinicians need to identify when reimbursement or legislation, not disease complexity, is driving missed reviews and fragmented care.
Multiple sclerosis care becomes inequitable early if women are offered lower-intensity disease-modifying therapy or slower escalation. Apply the same disease-activity thresholds regardless of sex, and when treatment pauses for pregnancy, document a restart date and early follow-up so high-efficacy therapy is not delayed without reason.
The pitfall is waiting for very frequent attacks before offering prevention. Open this for a concise update on anti-CGRP evidence, mood comorbidity, children with disabling migraine, and why preventive therapy may be reasonable even when the attack count still looks modest.
Migraine prevention should be discussed when headache disrupts work, school or family life, even if attacks are not frequent. A practical takeaway is to stop escalating acute medication alone and to use current guidance when considering earlier anti-CGRP or other preventive therapy.
Worth opening if your unit sees stroke. Late-presenting patients without large vessel occlusion may still enter a reperfusion pathway when imaging shows salvageable tissue, and adjunct intra-arterial alteplase after thrombectomy comes with selection, protocol and audit requirements.
For educators, the practical value lies in what generative AI can do in neurology training: draft vignettes, vary patient imagery, flag curriculum gaps and shape feedback. The episode is strongest when it also spells out the checks for bias, errors and confidentiality.
Adjunct dexamethasone should not be assumed to improve confirmed HSV encephalitis simply because it appears safe. In this phase III trial, 26-week outcomes, mortality, and discharge timing were similar to acyclovir alone, and the findings should not be extrapolated to undifferentiated encephalitis.
.svg)